Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.52 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.52 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HPGDS | O60760 | 2/20 | 0.47 |
| ▸ | MET | P08581 | 2/20 | 0.44 |
| ▸ | NQO2 | P16083 | 1/20 | 0.44 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.44 |
| ▸ | FEN1 | P39748 | 1/20 | 0.44 |
| ▸ | YAP1 | P46937 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12547063 | 0.92 | GPR119 (0.53) | GPR119SLC2A1CHEK2HDAC1HPGDS | |
| SCHEMBL12547517 | 0.91 | GPR119 (0.52) | GPR119SLC2A1CHEK2HDAC1HPGDS | |
| SCHEMBL22310712 | 0.91 | SLC2A1 (0.54) | GPR119SLC2A1CHEK2HDAC1HPGDS | |
| SCHEMBL2351366 | 0.89 | GPR119 (0.54) | GPR119SLC2A1CHEK2HDAC1HPGDS | |
| SCHEMBL22310368 | 0.88 | HPGDS (0.47) | GPR119CHEK2HPGDS | |
| SCHEMBL21264621 | 0.87 | SLC2A1 (0.51) | GPR119SLC2A1CHEK2HDAC1HPGDS | |
| SCHEMBL22309794 | 0.87 | GPR119 (0.54) | GPR119SLC2A1CHEK2HDAC1HPGDS | |
| SCHEMBL17078708 | 0.86 | SLC2A1 (0.60) | GPR119SLC2A1CHEK2HDAC1YAP1 | |
| SCHEMBL29222963 | 0.86 | SLC2A1 (0.47) | GPR119SLC2A1CHEK2HDAC1HPGDS | |
| SCHEMBL22310354 | 0.85 | GPR119 (0.45) | GPR119HPGDS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230056559-A1 | PYRIMIDINYL GROUP-CONTAINING TRICYCLIC COMPOUND SERVING AS C-MET INHIBITOR | JIANGSU AOSAIKANG PHARMACEUTICAL CO., LTD. (CN) | 2023-02-23 | — | — | US | disclosed |
| EP-3919492-A1 | PYRIMIDINYL GROUP-CONTAINING TRICYCLIC COMPOUND SERVING AS C-MET INHIBITOR | Medshine Discovery Inc. (CN) | 2021-12-08 | — | — | EP | disclosed |
| WO-2020156453-A1 | PYRIMIDINYL GROUP-CONTAINING TRICYCLIC COMPOUND SERVING AS C-MET INHIBITOR | 南京明德新药研发有限公司 | 2020-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230056559-A1 | PYRIMIDINYL GROUP-CONTAINING TRICYCLIC COMPOUND SERVING AS C-MET INHIBITOR | MET, MYC, METAP1 | GPR119 415/4885SLC2A1 721/4885CHEK2 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.